FIELD: medicine.
SUBSTANCE: present invention relates to combinations, methods and compositions for treating cancer, involving administering iadademstat in combination with a PD(L)1 inhibitor.
EFFECT: disclosed are combinations of adademstat for treating cancer.
28 cl, 2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| COMBINATIONS OF DUAL MODULATORS IRS/STAT3 AND ANTIBODIES TO PD-1/PD-L1 FOR CANCER TREATMENT | 2017 |
|
RU2796275C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| ADMINISTRATION OF SUMO-ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS | 2020 |
|
RU2830077C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| IMMUNE RESPONSE PRESERVATION DURING CHEMOTHERAPEUTICAL SHEMES | 2017 |
|
RU2779478C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| COMPOSITION FOR PREVENTING OR TREATING MALIGNANT TUMOUR, COMPRISING AGENT DESTROYING VESSELS, AND IMMUNE CONTROL POINT INHIBITOR | 2018 |
|
RU2738369C1 |
